Masimo Ahead, But Philips Fights On In Long-Running Patent Battle
This article was originally published in The Gray Sheet
A U.S. district court upheld an Oct. 2014 ruling finding Philips guilty of infringing two Masimo patents related to pulse oximetry technology, and awarded $467 million in damages, but Philips is appealing.
You may also be interested in...
Philips and Masimo have put to rest their long legal wrangling over patient-monitoring technology patents and shaken hands on a multi-year, global sales, and marketing partnership.
Myriad has sold several business units as it narrows its focus to oncology, women's health and mental health diagnostics. CEO Paul Diaz says the moves will allow the company to be a market leader.
US FDA’s Accelerated Approval process has always been a deceptively simple idea. After a three-day public review of ‘dangling’ applications, the underlying complexity remains.